Literature DB >> 17567882

Hepatoblastoma and heart transplantation in a patient with cardio-facio-cutaneous syndrome.

Mohamad M Al-Rahawan1, Deborah J Chute, Katia Sol-Church, Karen W Gripp, Deborah L Stabley, Nancy L McDaniel, William G Wilson, Peter E Waldron.   

Abstract

Cardio-facio-cutaneous syndrome (CFC) and Costello syndrome (CS) are disorders with an overlapping spectrum of congenital anomalies. Mutations in the RAS-MAPK pathway have recently been reported in both of these syndromes, with HRAS mutations characteristic for CS and BRAF and MEK1/2 mutations for CFC. We report on a 3-year-old boy who underwent a cardiac transplant at age 8 months for hypertrophic cardiomyopathy; he was subsequently suspected to have CS. At age 35 months he presented with an intra-cardiac mass that was diagnosed as metastatic hepatoblastoma. Although hepatoblastoma is not known to have an increased frequency in immunocompromised patients, questions were raised as whether the post-transplant immuno-suppressive therapy played a role in tumor development. The patient died shortly thereafter and his post-mortem DNA analysis revealed a MEK1 mutation (Y130C) previously reported in CFC. While CS is associated with increased cancer risk, only a single case of leukemia has been reported in a patient with CFC, making this the first case of a solid tumor reported in a patient with CFC. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17567882     DOI: 10.1002/ajmg.a.31819

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  10 in total

1.  Cardio-facio-cutaneous syndrome: does genotype predict phenotype?

Authors:  Judith E Allanson; Göran Annerén; Yoki Aoki; Christine M Armour; Marie-Louise Bondeson; Helene Cave; Karen W Gripp; Bronwyn Kerr; Anna-Maja Nystrom; Katia Sol-Church; Alain Verloes; Martin Zenker
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-14       Impact factor: 3.908

Review 2.  Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines.

Authors:  Mary Ella M Pierpont; Pilar L Magoulas; Saleh Adi; Maria Ines Kavamura; Giovanni Neri; Jacqueline Noonan; Elizabeth I Pierpont; Kent Reinker; Amy E Roberts; Suma Shankar; Joseph Sullivan; Melinda Wolford; Brenda Conger; Molly Santa Cruz; Katherine A Rauen
Journal:  Pediatrics       Date:  2014-09-01       Impact factor: 7.124

Review 3.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

4.  Congenital abnormalities and hepatoblastoma: a report from the Children's Oncology Group (COG) and the Utah Population Database (UPDB).

Authors:  Rajkumar Venkatramani; Logan G Spector; Michael Georgieff; Gail Tomlinson; Mark Krailo; Marcio Malogolowkin; Wendy Kohlmann; Karen Curtin; Rachel K Fonstad; Joshua D Schiffman
Journal:  Am J Med Genet A       Date:  2014-06-16       Impact factor: 2.802

5.  Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.

Authors:  Caroline Nava; Nadine Hanna; Caroline Michot; Sabrina Pereira; Nathalie Pouvreau; Tetsuya Niihori; Yoko Aoki; Yoichi Matsubara; Benoit Arveiler; Didier Lacombe; Eric Pasmant; Béatrice Parfait; Clarisse Baumann; Delphine Héron; Sabine Sigaudy; Annick Toutain; Marlène Rio; Alice Goldenberg; Bruno Leheup; Alain Verloes; Hélène Cavé
Journal:  J Med Genet       Date:  2007-08-17       Impact factor: 6.318

6.  Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

Authors:  Jenifer L Marks; Yixuan Gong; Dhananjay Chitale; Ben Golas; Michael D McLellan; Yumi Kasai; Li Ding; Elaine R Mardis; Richard K Wilson; David Solit; Ross Levine; Kathrin Michel; Roman K Thomas; Valerie W Rusch; Marc Ladanyi; William Pao
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

7.  Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Authors:  Rikhia Chakraborty; Oliver A Hampton; Xiaoyun Shen; Stephen J Simko; Albert Shih; Harshal Abhyankar; Karen Phaik Har Lim; Kyle R Covington; Lisa Trevino; Ninad Dewal; Donna M Muzny; Harshavardhan Doddapaneni; Jianhong Hu; Linghua Wang; Philip J Lupo; M John Hicks; Diana L Bonilla; Karen C Dwyer; Marie-Luise Berres; Poulikos I Poulikakos; Miriam Merad; Kenneth L McClain; David A Wheeler; Carl E Allen; D Williams Parsons
Journal:  Blood       Date:  2014-09-08       Impact factor: 22.113

8.  Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.

Authors:  Maria Lisa Dentici; Anna Sarkozy; Francesca Pantaleoni; Claudio Carta; Francesca Lepri; Rosangela Ferese; Viviana Cordeddu; Simone Martinelli; Silvana Briuglia; Maria Cristina Digilio; Giuseppe Zampino; Marco Tartaglia; Bruno Dallapiccola
Journal:  Eur J Hum Genet       Date:  2009-01-21       Impact factor: 4.246

Review 9.  Hepatoblastoma in molecularly defined, congenital diseases.

Authors:  Gunther Nussbaumer; Martin Benesch
Journal:  Am J Med Genet A       Date:  2022-04-28       Impact factor: 2.578

Review 10.  BRAF gene: From human cancers to developmental syndromes.

Authors:  Muhammad Ramzan Manwar Hussain; Mukhtiar Baig; Hussein Sheik Ali Mohamoud; Zaheer Ulhaq; Daniel C Hoessli; Ghaidaa Siraj Khogeer; Ranem Radwan Al-Sayed; Jumana Yousuf Al-Aama
Journal:  Saudi J Biol Sci       Date:  2014-10-23       Impact factor: 4.219

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.